eLetters

117 e-Letters

published between 2010 and 2013

  • Re:Neutrophils present in synovial fluids and tissues of rheumatoid arthritis are a major source of RANKL
    Dagmar Scheel-Toellner

    Dear Editor,

    We thank Poubelle et al for their interest in our publication "Cytokine mRNA profiling identifies B cells as a major source of RANKL in rheumatoid arthritis "[1]
    We share an enthusiasm with Professor Poubelle for the role of neutrophils in the pathophysiology of rheumatoid arthritis and agree that neutrophils are often the dominant cell population in rheumatoid synovial fluid.

    However, we disagr...

    Show More
  • Is sifalimumab a human anti-IFN alpha monoclonal antibody with a potential therapy for systemic lupus erythematosus?
    Wang-Dong Xu

    Dear editor,

    Merrill, et al. [1] reported that sifalimumab with safety profile and clinical activity was used in the phase I, multicentre, double-blind randomised study as an anti-IFN alpha monoclonal antibody in systemic lupus erythematosus (SLE), in which sifalimumab neutralized overexpression of the type I IFN signature in SLE patients in a dose-dependent manner as well as USP18/ESI-1 were inhibited, providing furthe...

    Show More
  • Corrected version of the e-letter "Selection bias may have blunted the effect of atorvastatin on the progression of atherosclerosis in systemic lupus erythematosus patients: Commentary on the Lupus Prevention Atherosclerosis Study (LAPS) "
    Markus Bredemeier

    Dear editor,

    We read with interest the study by Petri et al. (1), which showed absence of effect of atorvastatin on the change in coronary artery calcium and carotideal intima media thickness in lupus patients treated for 2 years. Lupus was been considered a coronary heart disease (CHD) equivalent by some authors given the major increase of cardiovascular risk in this disease (2).

    The authors reported that patie...

    Show More
  • Comment on: Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy
    Kosei Kawakami

    Dear Editor,

    We read with interest the recent article by Davies et al. [1] reporting on venous thrombotic events (VTEs) in patients with rheumatoid arthritis (RA) treated with antitumour necrosis factor (anti-TNF). They suggest that anti-TNF therapy is not associated with an increased risk of VTEs in RA patients, although, until the present time, retrospective studies looking at VTEs in anti-TNF-treated RA patients have...

    Show More
  • Neutrophils present in synovial fluids and tissues of rheumatoid arthritis are a major source of RANKL
    Patrice E. Poubelle

    Dear Editor,

    In a paper recently published online (Ann Rheum Dis, doi: 10.1136/ard.2011.153312), the authors found that B lymphocytes from rheumatoid arthritis (RA) synovial fluids and tissues expressed RANKL.
    They stated that B cells were a major source of this cytokine in RA without considering that certain other synovial fluid cells and tissular cells have been reported to express RANKL in RA. In fact, they did...

    Show More
  • Bone appearance in human tumor necrosis factor transgenic mice model: A model of rheumatoid arthritis or of hyperparathyroidism?
    Bruce M. Rothschild

    Dear Editor,

    Kollias et al. [1] presented an eloquent discussion of animal models of arthritis, remarking on their imperfect modeling of rheumatoid arthritis.
    Among the models discussed was the human tumor necrosis factor (TNF) transgenic mice model. Examination of images of bone damage2 in this model3 suggested a previously unrecognized, intriguing effect/role of TNF. We use the phrase bone damage, as the most imp...

    Show More
  • Early diagnosis will further add years to life of patients with vasculitis
    Piero Stratta

    Dear Editor,

    In a recent paper dealing with long term outcome of vasculitis, the authors conclude that "despite recent advances in treatment, patients with ANCA-associated vasculitis continue to have an excess mortality, ..." and ..."it is unclear to what extent improved treatments will have an impact on later mortality" [1].
    On the basis of our experience on 101 patients with vasculitis, 94 with histological dia...

    Show More
  • Response to eLetter by Felson and collaborators
    Jean-Pierre Pelletier

    Dear Editor,

    In response to the eLetter of Felson and collaborators, we wish to point out that the methodologies used in the present study have been extensively validated and found to be reliable in the context of multicenter clinical trials [1-3]. Most of the comments made by Felson and collaborators reflect their experience from observational studies which may or may not apply to clinical trials.

    Regarding the...

    Show More
  • About Lupus Atherosclerosis Prevention Study (LAPS)
    JM Sabio

    Dear Editor,

    We read with great interest the article of Petri et al [1] addressing the effect of atorvastatin 40 mg daily on subclinical atherosclerosis (ATS), systemic inflammation and disease activity in patients with systemic lupus erythematosus (SLE). Contrary to expectations, atorvastain had no effect on any of these parameters after 2 years of follup-up. Although these findings are clinically relevant, some issues...

    Show More
  • A possible effect of anti TNF therapy on fertility
    SAID Y. YOUNIS

    Dear Editor,

    Little data has addressed the issue of male fertility on anti TNF Therapy. The recent article by Villiger and colleagues in this journal suggested that sperm quality of patients with spondyloarthritis receiving long term anti TNF inhibition therapy was comparable to that in healthy controls and imputed reassurance for male patients treated with anti TNF therapy for fatherhood.

    We report herein one...

    Show More

Pages